uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - uniQure (NASDAQ:QURE)

uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related serious adverse events.

Raccontata dabenzinga.com